NCT02867956 2026-03-10
Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
Sun Yat-sen University
Phase 2 Completed
Clinical Trials
34 trialsNCT03083041 2026-03-03
A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT05235100 2025-12-11
SPARE-02
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT05156970 2025-07-31
Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Completed
NCT04625803 2025-06-17
Neoadjuvant Therapy for Locally Advanced Colon Cancer
Zhejiang University
Phase 2 Completed
NCT04195828 2025-04-01
Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer
Fujian Medical University
Phase 2 Completed
NCT04869488 2025-01-24
A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT03878472 2024-12-16
Neoadjuvant Immunotherapy for Resectable Gastric Cancer
Qilu Hospital of Shandong University
Phase 2 Completed
NCT03417895 2024-08-07
PASSION
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT04720131 2024-01-30
Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.
Beijing Friendship Hospital
Phase 2 Completed
NCT03472365 2024-01-11
A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT03267121 2023-10-17
A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Completed
NCT03180476 2023-04-14
Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma
Sichuan Cancer Hospital and Research Institute
Phase 2 Completed
NCT02976896 2023-02-16
Poetry-1
Sun Yat-sen University
Phase 2 Completed
NCT05025033 2023-01-18
Chemotherapy Combined With Apatinib and PD-1 Antibody
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Completed
NCT04350190 2023-01-13
Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Guilin Medical University, China
Phase 2 Completed
NCT02945852 2022-07-19
Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.
Zhejiang Cancer Hospital
Phase 2 Completed
NCT03104283 2022-03-15
Apatinib for the Elderly Advanced Gastric Cancer
Affiliated Hospital of Qinghai University
Phase 2 Completed
NCT04188847 2022-03-15
First-line Chemotherapy for Recurrent Cervical Cancer
Peking Union Medical College Hospital
Phase 2 Completed
NCT03243838 2022-02-02
LANCET
Guangdong Provincial People's Hospital
Phase 2 Completed
NCT02731352 2022-01-20
Study of Apatinib in Patients With Differentiated Thyroid Cancer
Peking Union Medical College Hospital
Phase 2 Completed
NCT04047017 2021-07-30
GTN
Peking Union Medical College Hospital
Phase 2 Completed
NCT04642664 2021-06-03
ACABC
Peking Union Medical College Hospital
Phase 2 Completed
NCT02878057 2021-01-27
Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)
Peking University Cancer Hospital & Institute
Phase 2 Completed
NCT03274011 2021-01-26
Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Fudan University
Phase 2 Completed
NCT03251443 2020-12-02
A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Peking Union Medical College Hospital
Phase 2 Completed
NCT03547804 2020-12-01
MK 01
The First Hospital of Jilin University
Phase 2 Completed
NCT04338438 2020-11-10
Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer
Beijing Friendship Hospital
Phase 2 Completed
NCT03394287 2020-10-23
A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Completed
NCT03660761 2019-04-16
Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors
Shandong Cancer Hospital and Institute
Phase 2 Completed
NCT01176669 2015-09-09
Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients
Fudan University
Phase 2 Completed
NCT01531777 2015-04-03
Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT01653561 2013-12-03
A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer
Fudan University
Phase 2 Completed
NCT01270386 2012-02-10
A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed